Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist that inhibits platelet aggregation. It is part of a dual antiplatelet therapy (DAPT) regimen.
## Primary Indications
* Reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
* Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) and at least one additional risk factor for occlusive vascular disease.
## Adult Dosing
* **ACS:**
* *Loading Dose:* 180 mg orally once.
* *Maintenance Dose:* 90 mg orally twice daily for at least 12 months, or longer if tolerated and indicated.
* *After initial loading dose, continue with 90 mg twice daily.*
* **History of MI (at least one risk factor):**
* 60 mg orally twice daily. This indication is generally for patients who have discontinued DAPT and are not candidates for, or are not on, oral anticoagulation.
## Pediatric Dosing
Dosing for pediatric patients is not established.
## Dose Adjustments
No dose adjustments are required for renal or hepatic impairment. However, caution is advised in severe hepatic impairment.
## Contraindications
* Active pathological bleeding (e.g., intracranial hemorrhage, gastrointestinal bleeding).
* History of prior transient ischemic attack (TIA) or stroke.
* Known hypersensitivity to ticagrelor or any of its components.
* Concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin).
## Adverse Effects
* **Major Bleeding:** The most common and serious adverse effect.
* **Dyspnea:** Transient, often resolves with continued therapy.
* **Bradycardia:**
* **Gout and hyperuricemia:**
* **Increased serum creatinine:**
* **Ventricular pauses:**
## Key Drug Interactions
* **CYP3A4 Substrates:** Ticagrelor is a moderate inhibitor of CYP3A4. Avoid concomitant use with sensitive CYP3A4 substrates (e.g., simvastatin, lovastatin) and consider dose reduction if coadministration is necessary.
* **CYP3A4 Inducers:** May decrease ticagrelor exposure (e.g., rifampin, phenytoin, carbamazepine, St. John's Wort).
* **P-glycoprotein (P-gp) Substrates:** Ticagrelor may inhibit P-gp. Increased exposure to P-gp substrates (e.g., digoxin) may occur.
* **Aspirin:** Generally coadministered in DAPT. Higher doses of aspirin (>300 mg daily) may reduce the efficacy of ticagrelor.
* **Oral Anticoagulants:** Increased risk of bleeding.
## Monitoring
* **Bleeding:** Closely monitor for any signs or symptoms of bleeding.
* **Renal Function:** Monitor serum creatinine.
* **Uric Acid Levels:** Consider monitoring in patients with a history of gout or hyperuricemia.
* **Heart Rate:** Assess for bradycardia.
## Clinical Pearls
* Ticagrelor is administered twice daily, unlike clopidogrel.
* It is not a prodrug and does not require metabolic activation.
* The 180 mg loading dose for ACS is crucial for rapid platelet inhibition.
* Discontinuation of ticagrelor prematurely increases the risk of thrombotic events.
* Patients experiencing significant dyspnea should be evaluated, but often can continue therapy if benefits outweigh risks.
***
*This information is intended for healthcare professionals. Please consult the current prescribing information and relevant clinical guidelines for complete details and to confirm drug information before making clinical decisions.*
